Clinical features of the course of Graves' disease in children

Cover Page

Cite item


Aim. To evaluate the features of the course and treatment of Graves' disease in children at the present stage.

Materials and methods. Thirty two children diagnosed with Graves' disease aged 5.5 to 16.5 years were examined; 19 girls and 5 boys were admitted to the department for the first time, 6 girls and 2 boys with relapses of the disease. The duration of the disease in these children ranged from 2 to 8 years, the number of relapses was from 2 to 4, the intervals for the onset of relapse of the disease ranged from 6 months to 2 years. The examination algorithm included the study of the anamnesis of life and disease, the assessment of objective data. Thyroid ultrasound was performed on a GE Healthcare Medical Systems Vivid machine. The level of thyroid hormones was determined: triiodothyronine, thyroxine, thyroid-stimulating hormone (TSH), the level of antibodies to the microsomal fraction with the IMMULITE 2000 XPi and ARCHTESTo2000SR kits (Siemens, Abbott, Germany) and antibodies to the TSH receptor with the ARCHTESTo2000SR kits (Abbott, USA).

Results. During an objective examination, tachycardia was determined in all children, an increase in the thyroid gland was noted. Almost all children had eye symptoms. The level of thyroid hormones was elevated in all children, both newly diagnosed and those admitted with a relapse of the disease. The level of TSH in all patients was reduced. The antibody titer was high for both the microsomal fraction and the TSH receptor. All patients admitted for the first time were prescribed drug therapy with thyreostatics. Three out of eight children with a recurrence of the disease were referred for radioactive iodine treatment and 1 for surgical treatment. The remaining four children continued drug treatment with thyreostatics, due to the parents' disagreement with other methods of treatment.

Conclusion. Thus, despite the pronounced manifestations of Graves' disease, almost all children had a late diagnosis of the disease: from the moment the complaints appeared to the diagnosis and start of treatment, it took from 4 months to 1 year. Initially, the children were treated and treated by specialists in various fields. Relapses of the disease, as a rule, developed after discontinuation of therapy, either after the end of the recommended treatment period (2 years), or at different times, due to self-cessation of treatment. In some patients, unreasonably long treatment with thyreostatics was noted, despite the development of: 3–4 relapses of the disease and the ineffectiveness of conservative therapy.

Full Text

Restricted Access

About the authors

Nina V. Bolotova

Razumovsky Saratov State Medical University

ORCID iD: 0000-0002-8148-526X
SPIN-code: 5061-1600

D. Sci. (Med.), Razumovsky Saratov State Medical University

Russian Federation, Saratov

Natalia Iu. Filina

Razumovsky Saratov State Medical University

Author for correspondence.
ORCID iD: 0000-0002-1613-4156
SPIN-code: 3390-1811

D. Sci. (Med.), Razumovsky Saratov State Medical University

Russian Federation, Saratov

Vadim K. Polyakov

Razumovsky Saratov State Medical University

ORCID iD: 0000-0001-6162-7884
SPIN-code: 9928-9682

D. Sci. (Med.), Razumovsky Saratov State Medical University

Russian Federation, Saratov

Sergei Iu. Aldashkin

Razumovsky Saratov State Medical University

ORCID iD: 0000-0003-0986-1811
SPIN-code: 9325-2354

Аssistant, Razumovsky Saratov State Medical University

Russian Federation, Saratov

Arina O. Fedotova

Razumovsky Saratov State Medical University

ORCID iD: 0000-0002-1357-1203

Student, Razumovsky Saratov State Medical University

Russian Federation, Saratov


  1. Трошина Е.А., Платонова Н.М., Панфилова Е.А. Аналитический обзор результатов мониторинга основных эпидемиологических характеристик йододефицитных заболеваний у населения Российской Федерации за период 2009–2018 гг. Проблемы эндокринологии. 2021;67(2):10-9 [Troshina EA, Platonova NM, Panfilova EA. Analytical review of the results of monitoring the main epidemiological characteristics of iodine deficiency diseases in the population of the Russian Federation for the period 2009–2018. Problems of endocrinology. 2021;67(2):10-9 (in Russian)]. doi: 10.14341/probl9308
  2. Шилин Д.E. Диффузный токсический зоб у детей: анализ заболеваемости на йоддефицитных территорих Российской Федерации. Проблемы эндокринологии. 2001;47(6):19-22 [Shilin DE. Diffuse toxic goiter in children: analysis of morbidity in iodine-deficient territories of the Russian Federation. Problems of Endocrinology. 2001;47(6):19-22 (in Russian)]. doi: 10.14341/probl11731
  3. Rivkees SA. Pediatric Graves' disease: controversies in management. Horm Res Paediatr. 2010;74(5):305-11. doi: 10.1159/000320028
  4. Kaguelidou F, Carel JC, Léger J. Graves' disease in childhood: advances in management with antithyroid drug therapy. Horm Res. 2009;71(6):310-7. doi: 10.1159/000223414
  5. McCormack S, Mitchell DM, Woo M, et al. Radioactive iodine for hyperthyroidism in children and adolescents: referral rate and response to treatment. Clin Endocrinol (Oxf). 2009;71(6):884-91. doi: 10.1111/j.1365-2265.2009.03565.x
  6. Cooper DS. Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab. 2003;88(8):3474-81. doi: 10.1210/jc.2003-030185
  7. Kaguelidou F, Alberti C, Castanet M, et al. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab. 2008;93(10):3817-26. doi: 10.1210/jc.2008-0842
  8. Александров А.А., Кисляк О.А., Леонтьева И.В. от имени экспертов. Клинические рекомендации. Диагностика, лечение и профилактика артериальной гипертензии у детей и подростков. Системные гипертензии. 2020;17(2):7-35 [Aleksandrov AA, Kislyak OA, Leont'eva IV on behalf of the experts. Clinical guidelines. Diagnosis, treatment and prevention of arterial hypertension in children and adolescents. Systemic hypertension. 2020;17(2):7-35 (in Russian)]. doi: 10.26442/2075082X.2020.2.200126
  9. Петунина Н.А., Трухина Л.В., Мартиросян Н.С. Болезнь Грейвса: современный взгляд на вопросы лечения. Эффективная фармакотерапия. 2011;48:24-9 [Petunina NA, Trukhina LV, Martirosyan NS. Graves' disease: a modern view on the issues of treatment. Effective pharmacotherapy. 2011;48:24-9 (in Russian)].
  10. Пашенцева А.В., Вербовой А.Ф. Диффузный токсический зоб. Клиническая медицина. 2017;95(9):780-8 [Pashentseva AV, Verbovoy AF. Diffuse toxic goiter. Clinical medicine. 2017;95(9):780-8 (in Russian)].
  11. Фадеев В.В. Диагностика и лечение болезни Грейвса. Медицинский совет. 2014;4:44-9 [Fadeev VV. Diagnosis and treatment of Graves' disease. Medical Council. 2014;4:44-9 (in Russian)].
  12. Дедов И.И., Трошина Е.А., Антонова С.С., и др. Аутоиммунные заболевания щитовидной железы: состояние проблемы. Проблемы эндокринологии. 2002;48(2):6-13 [Dedov II, Troshina EA, Antonova SS, et al. Autoimmune thyroid diseases: state of the problem. Problems of Endocrinology. 2002;48(2):6-13 (in Russian)]. doi: 10.14341/probl11500
  13. Безлепкина О.Б. Федеральные клинические рекомендации по диагностике и лечению болезни Грейвса у детей. Проблемы эндокринологии. 2014;60(3):59-68 [Bezlepkina OB. Federal clinical guidelines for the diagnosis and treatment of Graves' disease in children. Problems of endocrinology. 2014;60(3):59-68 (in Russian)].
  14. Бровкина А.Ф. Эндокринная офтальмопатия: реальность и перспективы. Офтальмологические ведомости. 2012;5(2):31-4 [Brovkina AF. Endocrine ophthalmopathy: reality and prospects. Ophthalmological records. 2012;5(2):31-4 (in Russian)].
  15. Laurberg P. Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism? Eur J Endocrinol. 2006;155(6):783-6. doi: 10.1530/eje.1.02295
  16. Rivkees SA. Controversies in the management of Graves' disease in children. J Endocrinol Invest. 2016;39(11):1247-57. doi: 10.1007/s40618-016-0477-x

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74329 от 19.11.2018 г.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies